[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunoparalysis-in-septic-shock\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunoparalysis-in-septic-shock":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100622823","artice-real-data-collection--observational-trial-phase-4-study-100622823",false,"NCT07388628","ARTICE® Real Data Collection & Observational Trial, Phase 4 Study","ARTISTRY - ARTICE® Therapy Registry Study","ARTistry","Inclusion Criteria:\n\n* Subjects ≥ 18 years who are planned to receive ARTICE® treatment during their ICU stay\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","7 Days","OBSERVATIONAL","The objectives of this registry study are to:\n\n1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects.\n2. Further evaluate ARTICE® treatment efficacy.\n3. Identify potential sub-groups, assess their risk-benefit- and safety profile.\n4. Changes in SOFA score D0 to SOFA Score D7.",[26,27,28],"Sepsis","Septic Shock","Immunoparalysis in Septic Shock",[26,30,28],"septic shock","RECRUITING","2026-02-06",{"date":34,"type":35},"2026-02-09","ACTUAL",{"date":37,"type":35},"2025-09-25",{"date":39,"type":21},"2027-12",{"name":41,"class":42},"Artcline GmbH","INDUSTRY"]